File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Adiponectin and cardiovascular health: An update

TitleAdiponectin and cardiovascular health: An update
Authors
Keywordsadipokine
adiponectin
cardiovascular disease
endothelial dysfunction
inflammation
obesity
vasculature
Issue Date2012
PublisherJohn Wiley & Sons Ltd. The Journal's web site is located at http://www.wiley.com/bw/journal.asp?ref=0007-1188&site=1
Citation
British Journal of Pharmacology, 2012, v. 165 n. 3, p. 574-590 How to Cite?
AbstractThe global epidemic of obesity is accompanied by an increased prevalence of cardiovascular disease (CVD), in particular stroke and heart attack. Dysfunctional adipose tissue links obesity to CVD by secreting a multitude of bioactive lipids and pro-inflammatory factors (adipokines) with detrimental effects on the cardiovascular system. Adiponectin is one of the few adipokines that possesses multiple salutary effects on insulin sensitivity and cardiovascular health. Clinical investigations have identified adiponectin deficiency (hypoadiponectinaemia) as an independent risk factor for CVD. In animals, elevation of plasma adiponectin by either pharmacological or genetic approaches alleviates obesity-induced endothelial dysfunction and hypertension, and also prevents atherosclerosis, myocardial infarction and diabetic cardiomyopathy. Furthermore, many therapeutic benefits of the peroxisome-proliferator activated receptor gamma agonists, the thiazolidinediones, are mediated by induction of adiponectin. Adiponectin protects cardiovascular health through its vasodilator, anti-apoptotic, anti-inflammatory and anti-oxidative activities in both cardiac and vascular cells. This review summarizes recent findings in the understanding of the physiological role and clinical relevance of adiponectin in cardiovascular health, and in the identification of the receptor and postreceptor signalling events that mediate the cardiovascular actions of adiponectin. It also discusses adiponectin-targeted drug discovery strategies for treating obesity, diabetes and CVD. Linked Articles This article is part of a themed section on Fat and Vascular Responsiveness. To view the other articles in this section visit © 2011 The British Pharmacological Society.
Persistent Identifierhttp://hdl.handle.net/10722/146888
ISSN
2014 Impact Factor: 4.842
2014 SCImago Journal Rankings: 1.844
PubMed Central ID
ISI Accession Number ID
Funding AgencyGrant Number
Research Grants Council of Hong KongHKU 2/07C
HKU4/CRF/10
Funding Information:

This work was supported by collaborative research fund (HKU 2/07C and HKU4/CRF/10) from the Research Grants Council of Hong Kong.

References
Grants

 

DC FieldValueLanguage
dc.contributor.authorHui, Xen_HK
dc.contributor.authorLam, KSLen_HK
dc.contributor.authorVanhoutte, PMen_HK
dc.contributor.authorXu, Aen_HK
dc.date.accessioned2012-05-23T05:48:30Z-
dc.date.available2012-05-23T05:48:30Z-
dc.date.issued2012en_HK
dc.identifier.citationBritish Journal of Pharmacology, 2012, v. 165 n. 3, p. 574-590en_HK
dc.identifier.issn0007-1188en_HK
dc.identifier.urihttp://hdl.handle.net/10722/146888-
dc.description.abstractThe global epidemic of obesity is accompanied by an increased prevalence of cardiovascular disease (CVD), in particular stroke and heart attack. Dysfunctional adipose tissue links obesity to CVD by secreting a multitude of bioactive lipids and pro-inflammatory factors (adipokines) with detrimental effects on the cardiovascular system. Adiponectin is one of the few adipokines that possesses multiple salutary effects on insulin sensitivity and cardiovascular health. Clinical investigations have identified adiponectin deficiency (hypoadiponectinaemia) as an independent risk factor for CVD. In animals, elevation of plasma adiponectin by either pharmacological or genetic approaches alleviates obesity-induced endothelial dysfunction and hypertension, and also prevents atherosclerosis, myocardial infarction and diabetic cardiomyopathy. Furthermore, many therapeutic benefits of the peroxisome-proliferator activated receptor gamma agonists, the thiazolidinediones, are mediated by induction of adiponectin. Adiponectin protects cardiovascular health through its vasodilator, anti-apoptotic, anti-inflammatory and anti-oxidative activities in both cardiac and vascular cells. This review summarizes recent findings in the understanding of the physiological role and clinical relevance of adiponectin in cardiovascular health, and in the identification of the receptor and postreceptor signalling events that mediate the cardiovascular actions of adiponectin. It also discusses adiponectin-targeted drug discovery strategies for treating obesity, diabetes and CVD. Linked Articles This article is part of a themed section on Fat and Vascular Responsiveness. To view the other articles in this section visit © 2011 The British Pharmacological Society.en_HK
dc.languageengen_US
dc.publisherJohn Wiley & Sons Ltd. The Journal's web site is located at http://www.wiley.com/bw/journal.asp?ref=0007-1188&site=1en_HK
dc.relation.ispartofBritish Journal of Pharmacologyen_HK
dc.rightsBritish Journal of Pharmacology. Copyright © John Wiley & Sons Ltd.-
dc.subjectadipokineen_HK
dc.subjectadiponectinen_HK
dc.subjectcardiovascular diseaseen_HK
dc.subjectendothelial dysfunctionen_HK
dc.subjectinflammationen_HK
dc.subjectobesityen_HK
dc.subjectvasculatureen_HK
dc.subject.meshAdiponectin - metabolismen_HK
dc.subject.meshBiological Markersen_HK
dc.subject.meshCardiovascular Diseases - metabolism - prevention and controlen_HK
dc.subject.meshReceptors, Adiponectin - metabolismen_HK
dc.subject.meshThiazolidinediones - therapeutic useen_HK
dc.titleAdiponectin and cardiovascular health: An updateen_HK
dc.typeArticleen_HK
dc.identifier.emailVanhoutte, PM: vanhoutt@hku.hken_HK
dc.identifier.emailXu, A: amxu@hkucc.hku.hken_HK
dc.identifier.authorityVanhoutte, PM=rp00238en_HK
dc.identifier.authorityXu, A=rp00485en_HK
dc.description.naturelink_to_OA_fulltext-
dc.identifier.doi10.1111/j.1476-5381.2011.01395.xen_HK
dc.identifier.pmid21457225-
dc.identifier.pmcidPMC3315032-
dc.identifier.scopuseid_2-s2.0-81855177709en_HK
dc.identifier.hkuros199771en_US
dc.identifier.hkuros213324-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-81855177709&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume165en_HK
dc.identifier.issue3en_HK
dc.identifier.spage574en_HK
dc.identifier.epage590en_HK
dc.identifier.isiWOS:000298953100004-
dc.publisher.placeUnited Kingdomen_HK
dc.relation.projectVascular dysfunction in obesity and diabetes: from risk prediction to therapeutic intervention-
dc.relation.projectA Multi-disciplinary Approach to Investigate Vascular Dysfunction in Obesity and Diabetes: From Molecular Mechanism to Therapeutic Intervention-
dc.identifier.scopusauthoridHui, X=26666795900en_HK
dc.identifier.scopusauthoridLam, KS=37008409400en_HK
dc.identifier.scopusauthoridVanhoutte, PM=7202304247en_HK
dc.identifier.scopusauthoridXu, A=7202655409en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats